HealthDay - SUNDAY, Aug. 21 (HealthDay News) -- An experimental drug that's shown promise against ovarian cancer caused by mutations in the BRCA1 or BRCA2 genes may also be effective against ovarian cancer not caused by those gene mutations, according to a new study.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.